Silk 'chips' capable of diagnosing a range of diseases in a matter of minutes could be ready for market by early 2013.

Global funding for R&D on neglected diseases has suffered a blow, with funders pulling out in the wake of the economic crisis.

A big cut in donor commitments to the global health fund has forced the agency to cancel new programmes.

A new trial has found that tenofovir gel, previously found to be effective, does not prevent HIV infection.

The inaugural Olusegun Obasanjo Prize has been awarded to HIV/AIDS researchers Salim S. and Quarraisha Abdool Karim.

Indian company Aurobindo Pharma will manufacture several antiretroviral medicines licensed to the Medicines Patent Pool.

A study from the Dominican Republic shows that soccer can be a tool for improving teenagers’ knowledge of HIV/AIDS.

A panel including Nobel laureate economists has said that vaccine research is the biggest HIV/AIDS funding priority.

A panel set up to review the finances of the Global Fund after the misuse of its grants has recommended a substantial overhaul.

A small and portable chip is as accurate at diagnosing HIV/AIDS as are standard laboratory tests, says a study.

Latin America and the Caribbean have reduced hunger and infant deaths but face delays reaching goals on education, deforestation and HIV.

Most neglected diseases are in retreat in Brazil and remaining challenges include reducing caesarean sections and non-infectious diseases.

Researchers have shown that anti-retrovirals can prevent HIV transmission, with a protection rate of 96 per cent.

A new centre will train African researchers to develop drugs for diseases neglected by large pharmaceutical companies.

The first-of-its-kind searchable website is expected to help researchers and policymakers deal with the disease.

A gadget that circumcises without the need for skilled personnel is to be rolled out in Rwanda, though the WHO has yet to approve it.

The Medicines Patent Pool is in negotiations with its first possible contributors, including GlaxoSmithKline.

The South African government is funding safety and efficacy trials of an HIV treatment developed from the 'cancer bush' Sutherlandia.

The testing and rolling out of new approaches to AIDS is too complex and time-consuming, Bill Gates says in his latest annual letter.

Anti-retroviral drugs, hitherto taken to treat HIV infection, have been shown to be effective at preventing it too.